HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.01 per share
Symbol
HRTX on Nasdaq
Shares outstanding
183,255,226
Price per share
$1.30
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
152,658,767
Total reported value
$192,362,843
% of total 13F portfolios
0%
Share change
+21,166,310
Value change
+$22,498,799
Number of holders
171
Price from insider filings
$1.30
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Rubric Capital Management LP 16% -8.9% $37,859,003 +$1,192,086 30,046,828 +3.3% Rubric Capital Management LP 15 Oct 2025
Clearline Capital LP 5.3% $11,655,032 9,712,527 Clearline Capital LP 30 Sep 2025
VANGUARD GROUP INC 4.6% $10,659,328 8,459,784 The Vanguard Group 30 Sep 2025
As of 30 Sep 2025, HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX) has 171 institutional shareholders filing 13F forms. They hold 152,658,767 shares. of 183,255,226 outstanding shares (83%) .

Top 25 institutional shareholders own 73% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Rubric Capital Management LP 16% 29,100,728 +8.9% 0.49% $36,666,917
ADAGE CAPITAL PARTNERS GP, L.L.C. 5.6% 10,239,225 +30% 0.02% $12,901,424
BlackRock, Inc. 5.5% 9,987,460 -1.1% 0% $12,584,200
Clearline Capital LP 5.3% 9,712,527 +1033% 1.1% $12,237,784
Velan Capital Investment Management LP 4.8% 8,753,290 +25% 10% $11,029,145
VANGUARD GROUP INC 4.6% 8,459,784 -0.14% 0% $10,659,328
PALISADE CAPITAL MANAGEMENT, LP 4% 7,327,447 +44% 0.25% $9,232,583
Tejara Capital Ltd 2.5% 4,589,715 +1.6% 3.2% $5,783,041
BAKER BROS. ADVISORS LP 2.3% 4,251,951 0.04% $5,357,458
STATE STREET CORP 2% 3,651,503 +5.5% 0% $4,600,894
GEODE CAPITAL MANAGEMENT, LLC 2% 3,642,982 +2.1% 0% $4,591,019
TANG CAPITAL MANAGEMENT LLC 1.9% 3,450,000 +62% 0.17% $4,347,000
JW Asset Management, LLC 1.8% 3,292,633 +41% 2% $4,148,718
D. E. Shaw & Co., Inc. 1.7% 3,088,492 -3.5% 0% $3,891,500
UBS Group AG 1.6% 2,934,081 -7.9% 0% $3,696,943
Congress Park Capital LLC 1.6% 2,890,157 +27% 1.1% $3,641,598
RENAISSANCE TECHNOLOGIES LLC 1.6% 2,854,999 +6.2% 0% $3,597,299
CITADEL ADVISORS LLC 1.5% 2,708,457 +22% 0% $3,412,656
NEW YORK STATE COMMON RETIREMENT FUND 1.4% 2,576,716 +46% 0% $3,246,662
CITIGROUP INC 1.4% 2,476,529 +4667% 0% $3,120,427
MORGAN STANLEY 1.3% 2,468,041 -11% 0% $3,109,732
AQR CAPITAL MANAGEMENT LLC 1.1% 1,936,689 +3036% 0% $2,440,228
GOLDMAN SACHS GROUP INC 0.72% 1,324,802 +27% 0% $1,669,251
MARSHALL WACE, LLP 0.71% 1,308,861 -55% 0% $1,649,165
JPMORGAN CHASE & CO 0.71% 1,292,444 +36% 0% $1,628,479

Institutional Holders of HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 273,353 $355,669 -$23,603 $1.30 3
2025 Q3 152,658,767 $192,362,843 +$22,498,799 $1.26 171
2025 Q2 131,463,843 $272,131,676 +$12,999,478 $2.07 170
2025 Q1 124,770,231 $274,489,898 +$21,979,195 $2.20 164
2024 Q4 114,941,581 $175,829,179 -$13,146,397 $1.53 161
2024 Q3 121,816,811 $242,421,216 -$29,164,536 $1.99 169
2024 Q2 129,609,461 $453,638,008 +$35,415,047 $3.50 189
2024 Q1 119,262,673 $330,361,469 +$19,698,437 $2.77 157
2023 Q4 112,451,511 $191,165,565 +$1,074,277 $1.70 149
2023 Q3 118,378,841 $121,934,068 +$19,982,956 $1.03 138
2023 Q2 98,652,577 $114,435,495 -$11,706,623 $1.16 143
2023 Q1 107,852,430 $162,855,915 -$15,688,602 $1.51 153
2022 Q4 115,831,665 $289,582,111 -$29,877,564 $2.50 175
2022 Q3 121,963,764 $514,346,608 +$45,998,596 $4.22 178
2022 Q2 115,204,514 $321,404,107 +$4,826,591 $2.79 160
2022 Q1 108,535,070 $620,478,626 -$95,435,236 $5.72 176
2021 Q4 117,646,567 $1,073,655,355 +$78,398,633 $9.13 192
2021 Q3 108,488,554 $1,160,926,758 +$41,634,303 $10.69 189
2021 Q2 103,864,409 $1,612,145,175 +$202,378,763 $15.52 182
2021 Q1 89,846,972 $1,456,395,898 -$11,223,795 $16.21 186
2020 Q4 90,262,699 $1,910,380,366 +$26,526,144 $21.16 180
2020 Q3 90,857,946 $1,346,585,988 +$33,105,054 $14.82 177
2020 Q2 88,614,685 $1,334,393,703 -$51,210,796 $14.71 185
2020 Q1 92,095,623 $1,081,183,715 -$131,875,186 $11.74 186
2019 Q4 99,047,059 $2,326,444,060 +$183,809,453 $23.50 194
2019 Q3 91,435,188 $1,691,767,958 -$43,730,310 $18.50 175
2019 Q2 93,875,302 $1,744,712,239 +$2,233,456 $18.59 170
2019 Q1 92,662,760 $2,264,521,795 +$28,820,026 $24.44 189
2018 Q4 91,350,119 $2,369,031,974 +$92,438,916 $25.94 169
2018 Q3 87,463,202 $2,768,171,136 +$131,977,881 $31.65 187
2018 Q2 77,152,541 $2,997,578,965 +$216,890,926 $38.85 192
2018 Q1 72,567,037 $2,001,875,074 +$342,791,800 $27.60 149
2017 Q4 60,500,377 $1,095,067,241 +$103,341,807 $18.10 120
2017 Q3 63,406,329 $1,024,008,242 -$88,424,754 $16.15 101
2017 Q2 69,617,065 $964,195,934 +$47,548,351 $13.85 102
2017 Q1 71,661,852 $1,074,958,781 +$337,458,954 $15.00 98
2016 Q4 52,666,446 $689,938,271 +$4,719,852 $13.10 94
2016 Q3 51,265,727 $883,246,939 +$71,930,213 $17.23 88
2016 Q2 46,993,886 $848,220,501 +$35,391,534 $18.05 90
2016 Q1 45,017,464 $854,951,019 -$8,625,778 $18.99 98
2015 Q4 45,438,610 $1,214,308,493 +$39,761,438 $26.70 103
2015 Q3 43,669,932 $1,064,954,183 +$173,790,187 $24.40 101
2015 Q2 36,118,773 $1,125,171,985 +$319,523,410 $31.16 86
2015 Q1 26,445,484 $384,782,059 +$31,452,121 $14.55 68
2014 Q4 24,573,735 $247,206,453 +$2,536,942 $10.06 62
2014 Q3 24,229,222 $201,828,829 -$7,802,513 $8.33 56
2014 Q2 26,551,442 $327,060,299 +$69,901,807 $12.32 67
2014 Q1 20,801,929 $289,178,683 +$283,529,683 $13.91 39